Radioprotectors: Defensive Weapons In The War On Cancer 
Share This:
                           

About The Author

As Director of Operations & Corporate Development for EpicentRx, Mr. Caroen is highly skilled in Clinical Program Development, Effective Conduct of Clinical Trials, Good Clinical Practices, and Life Science Business Strategies. He is responsible for clinical development of RRx-001 and additionally helps to drive business development by prioritizing opportunities, conducting diligence, and transacting business and collaboration opportunities. Mr. Caroen is a co-author on over 40 peer reviewed scientific publications and co-inventor on 3 pending patents.

                       

Radioprotectors: Defensive Weapons In The War On Cancer 

In 1971, President Richard Nixon declared a war on cancer (though with the Vietnam war still ongoing, he never actually used that phrase, calling for “the conquest of cancer”1 instead). This metaphor has persisted and dominated to the present day2, providing the impetus to dose anti-cancer agents as close as possible to the maximally-tolerated dose, or MTD, beyond which the toxicities are unbearable in a usually futile attempt to eradicate or break the back of the disease. During the first...

Read more